Cabaletta Bio: all DM/ASyS myositis patients meet registrational endpoint; SSc and lupus data positive

Cabaletta Bio, Inc.

All 4 DM/ASyS patients with sufficient follow-up achieved immunomodulatory-free moderate or major TIS response at week 16.
Initiating DM/ASyS registrational cohort this quarter; plans 14 patients with 16-week primary endpoint of moderate or major TIS.
All 4 SSc patients with at least 3 months follow-up achieved rCRISS-25 response off all immunomodulators and steroids.
7 of 8 lupus patients with sufficient follow-up achieved DORIS remission or renal response; all 9 patients off immunomodulators.
Expanding RESET-SLE to include no preconditioning cohort; initial data expected 2026; 76 patients enrolled at 77 sites globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.